Imagine a world where predictive tools for development planning scour development programs and pharmaco-epidemiological real-world data to anticipate the response of patient populations. Where scenario analyses visualize strategic design trade-offs to optimize protocol design, and predictive assays select the right patients from integrated electronic health records across providers at a genome level. Where point-of-care data capture integrates trial evidence and real-world outcomes within clinical care systems, improving adherence and compliance to treatments. All this within biopharma’s heightened operational performance with cycle times reduced by a third and development costs cut in half. Delivered by organizations aligned across research and development (R&D), commercial and external partner functions where there is full role clarity and seamless, harmonized integration.

This whitepaper examines our view on the future of biopharmaceutical research and development.